TherapeuticsMD, Inc. (NASDAQ:TXMD) produced a 64.05% rally since recording the worst price of $3.51. Thanks to the latest 3.98% increase, it now trades at $5.75. Throughout the trading on 3/12/2019, the share price floated between $5.52 and $5.81. This company shares are 153.39% off its target price of $14.57 and the current market capitalization stands at $1.38B. The recent change has given its price a 10.5% lead over SMA 50 and -24.93% deficit over its 52-week high. The stock witnessed 9.94% gains, 26.93% gains and -6.5% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TXMD’s volatility during a week at 5.03% and during a month it has been found around 5.94%.TherapeuticsMD, Inc. (TXMD) Top Holders
Institutional investors currently hold around $1.03 billion or 78.7% in TXMD stock. Look at its top three institutional owners: Bank Of New York Mellon Corp owns $168.66 million in TherapeuticsMD, Inc., which represents roughly 12.22% of the company’s market cap and approximately 16.33% of the institutional ownership. Similar statistics are true for the second largest owner, Price T Rowe Associates Inc /Md/, which owns 21,522,345 shares of the stock are valued at $119.02 million. The third largest holder is Jpmorgan Chase & Co, which currently holds $109.7 million worth of this stock and that ownership represents nearly 7.95% of its market capitalization.
At the end of December reporting period, 68 institutional holders increased their position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by some 22,599,970 shares, 81 decreased positions by 14,027,088 and 27 held positions by 150,238,031. That puts total institutional holdings at 186,865,089 shares, according to SEC filings. The stock grabbed 22 new institutional investments totaling 4,390,772 shares while 34 institutional investors sold out their entire positions totaling 3,559,082 shares.TherapeuticsMD, Inc. (TXMD) Analyst Guide
Several analysts have released their opinion on TherapeuticsMD, Inc. (NASDAQ:TXMD), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.86 average brokerage recommendation [T1].